LONDON (Reuters) - GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back skeptical investors.
Reuters: Business News, Reuters: Business
Mon, 09/22/2014 - 4:36am
LONDON (Reuters) - GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back skeptical investors.